etftrends.com · 25 jun

Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

zacks.com · 24 jun

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

seekingalpha.com · 8 jun

Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

businesswire.com · 28 may

Veradermics to Present at Upcoming June Investor Conferences

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial.

gurufocus.com · 27 may

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics fo

businesswire.com · 27 may

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302' Study of VDPHL01 will be presented at the 2026 World Congress for Hair Research on May 30, 2026. The data to be presented includes positive topline results, shared by the company in April 2026, from Part A of its randomized, d.

businesswire.com · 14 may

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that two E-posters will be presented at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE) beginning today in Nashville, Tennessee until May 17, 2026. The data to be presented include two comparative analyses of VDPHL01's Phase 2 male data.

businesswire.com · 12 may

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress. “The announcement of positive Phase 2/3 topline results from Study ‘302' in April 2026 was an inflection point for Veradermics and supports our belief.